Tengborn L, Bergqvist D
Department for Coagulation Disorders, University of Lund, General Hospital, Malmö, Sweden.
Acta Chir Scand. 1988 Mar;154(3):179-83.
A retrospective study is presented of 23 patients with congenital antithrombin (AT) III deficiency who underwent 57 operations of various types. Thromboprophylaxis was given in 28 operations. Dextran was used in most cases, sometimes in combination with specific AT III concentrate. No patient given AT III concentrate alone or in combination with other methods had signs of thromboembolism. Deep venous thrombosis followed four of the operations with prophylaxis (3 patients). After the 29 operations without prophylaxis there were three cases of deep venous thrombosis, one with clinical signs of pulmonary embolism and another with superficial thrombophlebitis. Despite its inherent drawbacks, this retrospective study indicated that AT III concentrate can effectively prevent postoperative thromboembolism. But as the selection criteria for thromboprophylaxis are difficult to evaluate, a prospective study should be of great value.
对23例先天性抗凝血酶（AT）III缺乏症患者进行了回顾性研究，这些患者接受了57次各类手术。28次手术中进行了血栓预防。大多数情况下使用右旋糖酐，有时与特异性AT III浓缩物联合使用。单独使用AT III浓缩物或与其他方法联合使用的患者均无血栓栓塞迹象。在4次进行预防的手术（3例患者）后发生了深静脉血栓形成。在29次未进行预防的手术后，有3例深静脉血栓形成，1例有肺栓塞的临床体征，另1例有浅表血栓性静脉炎。尽管这项回顾性研究有其固有的缺陷，但表明AT III浓缩物可有效预防术后血栓栓塞。但由于血栓预防的选择标准难以评估，前瞻性研究将具有很大价值。
